Publications by authors named "Sebastien Hazard"

Claim this Profile
A
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer.
Laura M Spring, Hyo Han, Minetta C Liu, Erika Hamilton, Hanna Irie, Sebastien Hazard

Nat Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer.
Laura M Spring, Hyo Han, Minetta C Liu, Erika Hamilton, Hanna Irie, Sebastien Hazard

Nat Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Josep M Del Campo, Ursula A Matulonis, Susanne Malander, Diane Provencher, Sven Mahner, Sebastien J Hazard

J Clin Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased risk of brain metastases in ovarian cancer patients with BRCA mutations.
Elena Ratner, Mohan Bala, Melinda Louie-Gao, Ebru Aydin, Sebastien Hazard

Gynecol Oncol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
Michel Fabbro, Kathleen N Moore, Anne Dørum, Anna V Tinker, Sven Mahner, Sebastien J Hazard

Gynecol Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials.
Corey J Langer, Mark A Socinski, Jyoti D Patel, Alan B Sandler, Joan H Schiller, Sebastien J Hazard

Am J Clin Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices.
Orsolya E Lunacsek, Arliene Ravelo, Anna D Coutinho, Sebastien J Hazard, Mark R Green

Drugs Real World Outcomes· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of bevacizumab exposure beyond disease progression in patients with non-small-cell lung cancer: analyses of the ARIES observational cohort study.
Larry Leon, Michael Kosty, Mohammad Jahanzeb, David Spigel, Antoinette J Wozniak, Sebastien J Hazard

Pharmacoepidemiol Drug Saf· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study.
Michael P Kosty, Antoinette J Wozniak, Mohammad Jahanzeb, Larry Leon, Susan Fish, Sebastien J Hazard

Target Oncol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.
Corey Langer, Arliene Ravelo, Sebastien J Hazard, Annie Guerin, Raluca Ionescu-Ittu

Lung Cancer· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study.
Thomas J Lynch, David R Spigel, Julie Brahmer, Neal Fischbach, Jennifer Garst, Sebastien J Hazard

J Thorac Oncol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis